© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
June 07, 2021
Darolutamide is FDA-approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
Mark Christopher Markowski, MD, PhD, discusses phase 1b/2 data for the novel oral cytoskeletal disruptor VERU-111 in metastatic castration-resistant prostate cancer being presented during the 2021 ASCO Annual Meeting.
June 06, 2021
Neeraj Agarwal, MD, discusses health-related quality of life and patient-reported outcomes from the phase 3 TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.
June 04, 2021
Smruthy Sivakumar, PhD, discusses results from a large-scale analysis of ancestry, patterns of gene alterations, comprehensive genomic profiling, and treatment patterns in nearly 12,000 patients with prostate cancer.
The treatment was also well tolerated, results from an ongoing phase 1/2a dose escalation study indicate.
June 03, 2021
Overall survival and progression-free survival data from the phase 3 VISION trial were shared as part of the 2021 ASCO Annual Meeting.
June 01, 2021
Ahead of the 2021 ASCO Annual Meeting, Michael S. Cookson, MD, co-editor in chief of Urology Times, shared his thoughts on the most pivotal abstracts in genitourinary cancer.
May 19, 2021
Higher screening frequency was associated with a lower risk of metastatic disease at diagnosis and a reduction in prostate cancer–specific mortality.